Side Effects and Safety Considerations This is a high-level safety overview - not a complete list of risks or precautions, and not a substitute for the patient information provided with your prescription or guidance from your own healthcare provider
Coordination with endocrinology, primary care, or the prescribing clinician may be appropriate for patients with poor glycemic control, insulin use, chronic kidney disease, or high cardiovascular risk
In a phase 2 trial of obese patients with type 2 diabetes, CagriSema reduced glycated hemoglobin (HbA1c) levels
For physical activity, low physical activity, moderate physical activity and high physical activity were assigned to 0, 1, and 2 points, respectively
Theyre human